Needham Maintains OrthoPediatrics (KIDS) Buy Recommendation
Needham has reaffirmed its Buy rating for OrthoPediatrics (KIDS). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Lake Street Initiates Coverage of OrthoPediatrics (KIDS) with Buy Recommendation
Lake Street has initiated coverage of OrthoPediatrics (KIDS) with a "Buy" recommendation. The firm has set a price target of $55.00 for the company's stock. This new coverage suggests a positive outlook on OrthoPediatrics' future performance.
OrthoPediatrics establishes new $20 million delayed draw term loan facility
OrthoPediatrics Corp. (NASDAQ:KIDS) has secured a new delayed draw term loan facility of up to $20 million through an amendment to its existing credit agreement. This facility, with an interest rate based on SOFR plus 6.50% per annum, allows the company to draw capital in increments until June 30, 2027, and matures on August 5, 2029. The announcement follows a recent mixed earnings report where the company exceeded revenue expectations despite a wider-than-expected loss, and analysts like Needham raised their price target.
OrthoPediatrics (NASDAQ: KIDS) secures $20M delayed draw term loan
OrthoPediatrics Corp. (NASDAQ: KIDS) has amended its existing term loan agreement to include a new delayed draw term loan facility of up to $20.0 million. This facility provides the company with flexible access to capital in minimum $10.0 million increments until June 30, 2027, with interest at the SOFR rate plus 6.50% (with a 3.25% floor) and a 1.00% payment-in-kind option. The agreement aims to support future investments or working capital needs while preserving near-term cash flow, without requiring immediate drawing on the funds.
OrthoPediatrics Adds $20 Million Delayed-Draw Term Loan Facility Under Braidwell-Led Agreement
OrthoPediatrics (KIDS) has amended its Credit Agreement to include a $20 million delayed-draw term loan facility with Braidwell-managed funds, enhancing liquidity and capital deployment options. The facility offers flexible drawdowns until June 2027 and matures in August 2029, with interest at SOFR plus 6.50% and various fees. This move provides the company with financial flexibility while preserving near-term cash flow without immediate draw requirements.
OrthoPediatrics establishes new $20 million delayed draw term loan facility
OrthoPediatrics Corp. (NASDAQ:KIDS) has established a new $20 million delayed draw term loan facility through an amendment to its existing credit agreement. This facility allows the company to access capital in increments until June 30, 2027, with an interest rate based on SOFR plus 6.50% per annum. The move comes as the company maintains a strong current ratio and has shown revenue growth, despite a recent wider-than-expected loss per share in Q4 2025.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & Chief Executive Officer, Dave Bailey, and Chief Operating Officer & Chief Financial Officer, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. The event is scheduled for Tuesday, April 14, 2026, at 9:30 am ET, with an audio webcast and replay available on the company's investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering over 85 products across trauma and deformity, scoliosis, and sports medicine.
OrthoPediatrics CEO and CFO join live Needham webcast on April 14
OrthoPediatrics (NASDAQ: KIDS) announced that its CEO, Dave Bailey, and COO/CFO, Fred Hite, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, at 9:30 am ET. An audio webcast of the discussion will be available on the company’s investor relations website, with a replay accessible after the event. This participation follows a series of positive company developments, including record 2025 revenue and strong 2026 guidance.
OrthoPediatrics Corp Stock: Specialized Pediatric Orthopedics Leader Faces Sector Headwinds and Grow
OrthoPediatrics Corp (NASDAQ: KIDS) is highlighted as a leader in specialized pediatric orthopedic solutions, serving a niche market distinct from larger competitors. The company's business model involves direct sales of implants and devices for trauma, deformity, spine, and sports medicine in children, supported by ongoing R&D and strategic acquisitions. While benefiting from high barriers to entry and strong clinical evidence, investors should consider risks such as reimbursement changes, sales force dependence, and competitive pressures.
KIDS PE Ratio & Valuation, Is KIDS Overvalued
OrthoPediatrics Corp (KIDS) is currently considered undervalued, with a fair price estimated between $31.81 and $77.22 compared to its current price of $15.20, indicating it is undervalued by 52.22%. Despite being undervalued by this metric, its current P/S ratio of 1.30 is significantly above the industry average of 3.87 which is deemed unsustainable given its 16.97% revenue growth. The article also details KIDS's P/B ratio, FCF yield, Forward P/E, and Forward P/S ratios as of April 1, 2026.
OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. (Nasdaq: KIDS) announced that its President & CEO, Dave Bailey, and COO & CFO, Fred Hite, are scheduled to participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 9:30 am ET. An audio webcast will be available on the company's investor relations website. OrthoPediatrics focuses exclusively on advancing pediatric orthopedics with a comprehensive product offering.
KIDS SEC Filings - Orthopedia 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to OrthoPediatrics Corp. (KIDS) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside insider trading information. It details the company's financial condition, operations, and governance, with AI-powered summaries to help investors quickly understand key points. The site highlights recent filings such as insider trading activity and board changes, offering a centralized resource for regulatory disclosures.
OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of "Moderate Buy" by Brokerages
Eleven brokerages have given OrthoPediatrics Corp. (NASDAQ:KIDS) an average rating of "Moderate Buy," with an average 12-month price target of $24.67. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with a negative net margin, and analysts project a negative EPS for the current year. Insiders have sold 58,171 shares recently, though they still hold a substantial 32.7% of the company's stock, and institutions have significantly modified their holdings.
OrthoPediatrics (KIDS) COO/CFO granted shares, sells stock for taxes
OrthoPediatrics Corp. COO and CFO, Fred Hite, reported receiving a grant of 77,405 shares of common stock on March 15, 2026. He subsequently sold 12,993 shares at $17.25 each on March 16, 2026, to cover tax withholding obligations associated with restricted share vesting. Following these transactions, Hite directly owns 277,477 shares of OrthoPediatrics Common Stock, which includes 197,765 restricted stock awards.
OrthoPediatrics (KIDS) CEO share sale covers tax withholding on RSUs
OrthoPediatrics Corp. President and CEO David R. Bailey sold 19,535 shares of common stock at $17.25 per share. This sale was conducted to satisfy tax withholding obligations triggered by the vesting of restricted stock, not as a discretionary investment move. Following the transaction, Bailey retains 298,020 shares, including 187,891 restricted stock awards, maintaining a significant equity position in the company.
OrthoPediatrics (KIDS) president awarded shares, sells some for taxes
Gregory A. Odle, President of Scoliosis at OrthoPediatrics Corp. (KIDS), received a restricted stock award of 47,380 shares. Shortly after, he sold 8,433 shares to cover tax withholding obligations related to the vesting of these restricted shares. Following these transactions, Odle directly holds 187,735 shares, including 121,054 restricted stock awards.
OrthoPediatrics (KIDS) counsel gets 47,380-share grant, sells 8,614
OrthoPediatrics Corp.'s General Counsel, Daniel J. Gerritzen, was granted 47,380 shares of common stock at $0.00 per share on March 15, 2026. The following day, he sold 8,614 shares at $17.25 each to cover tax-withholding obligations related to the vesting of restricted shares. After these transactions, Gerritzen directly holds 149,533 shares of common stock, which includes 121,054 restricted stock awards.
Orthopediatrics (KIDS) executive reports stock grant and tax-related sale
Joseph W. Hauser, an executive at Orthopediatrics (KIDS), reported receiving a stock grant of 65,700 shares on March 15, 2026. Subsequently, 8,596 shares were sold at $17.25 each on March 16, 2026, to cover tax withholding obligations. After these transactions, Hauser directly holds 194,767 shares of Common Stock, including restricted stock awards.
Insider Selling: OrthoPediatrics (NASDAQ:KIDS) Insider Sells 8,596 Shares of Stock
OrthoPediatrics (NASDAQ:KIDS) insider Joseph Hauser sold 8,596 shares of the company's stock on March 16th, reducing his stake by 4.23%. The transaction, valued at $148,281, came as OrthoPediatrics reported better-than-expected Q4 earnings and maintains a "Moderate Buy" consensus rating from analysts. The stock traded up 0.6% to $17.21, with significant institutional investment activity also noted.
OrthoPediatrics (NASDAQ:KIDS) CEO David Bailey Sells 19,535 Shares
OrthoPediatrics CEO David Bailey sold 19,535 shares of the company's stock on March 16th for over $336,000, reducing his stake by 6.15%. Despite the sale, the company reported better-than-expected quarterly earnings and revenue, though it remains unprofitable. Analysts hold a "Moderate Buy" consensus rating for KIDS with an average price target of $24.67.
Insider Selling: OrthoPediatrics (NASDAQ:KIDS) General Counsel Sells 8,614 Shares of Stock
OrthoPediatrics General Counsel Daniel Gerritzen sold 8,614 shares of the company's stock for approximately $148,591.50 on March 16th, reducing his stake by 5.45%. Despite beating Q4 EPS estimates, OrthoPediatrics remains unprofitable. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $24.67.
[144] ORTHOPEDIATRICS CORP SEC Filing
This article details a Form 144 SEC filing by OrthoPediatrics Corp. (KIDS) dated March 16, 2026. The filing indicates a proposed sale of 8,433 shares of common stock by an unnamed person, acquired through restricted stock units, with an aggregate market value of $145,506. The sale is scheduled for March 16, 2026, via Stifel Nicolaus & Company Inc. on the Nasdaq exchange.
[144] ORTHOPEDIATRICS CORP SEC Filing
This article reports on an SEC Form 144 filing by OrthoPediatrics Corp. (KIDS). The filing indicates a proposed sale of 12,993 shares of common stock with an aggregate market value of $224,186.00, acquired on March 15, 2026, as restricted stock units through equity compensation. The sale is planned for March 16, 2026, on Nasdaq, via Stifel Nicolaus & Company Inc.
[144] ORTHOPEDIATRICS CORP SEC Filing
This article details an SEC Form 144 filing by OrthoPediatrics Corp. (KIDS) for a proposed sale of securities, specifically common stock, on March 16, 2026. The filing indicates a sale of 8,596 shares with an aggregate market value of $148,319.00 acquired through restricted stock units, and also provides recent news and financial data for the company.
Granahan Investment Management LLC Has $14.08 Million Stock Position in OrthoPediatrics Corp. $KIDS
Granahan Investment Management LLC significantly reduced its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 21.4% in the third quarter, holding 759,951 shares valued at $14.08 million. Despite this, other institutional investors have increased their positions. OrthoPediatrics recently reported better-than-expected quarterly earnings and has a "Moderate Buy" consensus rating from analysts.
Prosight Management LP Acquires 235,060 Shares of OrthoPediatrics Corp. $KIDS
Prosight Management LP significantly increased its stake in OrthoPediatrics Corp. (NASDAQ:KIDS) by 319.2% in the third quarter, purchasing an additional 235,060 shares, bringing its total ownership to 308,707 shares valued at $5.72 million. This investment now represents 1.23% of OrthoPediatrics and 1.3% of Prosight Management LP's portfolio. Other institutional investors like Millennium Management LLC, Goldman Sachs Group Inc., Marshall Wace LLP, and UBS Group AG also increased their positions in KIDS, indicating strong institutional interest in the medical device company.
[144] ORTHOPEDIATRICS CORP SEC Filing
This article details the filing of Form 144 by OrthoPediatrics Corp. (KIDS), indicating a proposed sale of securities under Rule 144. The filing specifies the sale of 8,614 shares of common stock with an aggregate market value of $148,629, acquired through Restricted Stock Units. The securities are to be sold via Stifel Nicolaus & Company Inc. on the Nasdaq exchange.
OrthoPediatrics Earnings Call Flags Profitable Turn
OrthoPediatrics Corp's latest earnings call revealed a positive financial inflection, with accelerated revenue growth, expanded margins, and the first quarter of positive free cash flow. Despite elevated losses and spending, the company views these as investments in a robust product pipeline and aims for profitability by 2026. Management reaffirmed its 2026 revenue outlook and highlighted strong demand across core franchises, product innovation, and international business rebound.
Orthopediatrics 2025 10-K: Revenue $236.3M, EPS $(1.69)
Orthopediatrics reported fiscal 2025 net revenue of $236.3 million, marking a 15% year-over-year increase, but also a net loss of $39.6 million, or $(1.69) per share, due to higher operating expenses and impairment charges. The company's gross margin remained consistent at 73%, and growth was driven by its Trauma and Scoliosis businesses, as well as contributions from recent acquisitions. Orthopediatrics expanded its international presence and utilized a consignment strategy for its product portfolio, which includes 87 systems.
OrthoPediatrics Corp. (NASDAQ:KIDS) Given Consensus Rating of "Moderate Buy" by Brokerages
OrthoPediatrics Corp. (NASDAQ:KIDS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 1-year price target of $24.67. The company recently beat EPS and revenue estimates but remains unprofitable. Institutional investors hold approximately 69% of the stock.
Wall Street Analysts See a 32.67% Upside in OrthoPediatrics (KIDS): Can the Stock Really Move This High?
OrthoPediatrics (KIDS) recently closed at $19.22, with Wall Street analysts setting a mean price target of $25.5, indicating a potential 32.7% upside. While empirical research suggests caution when relying solely on price targets, the company's strong Zacks Rank #2 (Buy) and positive trend in earnings estimate revisions provide a more reliable indicator of potential near-term upside. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
OrthoPediatrics (NASDAQ:KIDS) Price Target Raised to $20.00
Truist Financial has raised its price target for OrthoPediatrics (NASDAQ:KIDS) to $20.00 from $19.00, maintaining a "hold" rating, suggesting a 4.3% potential upside. Despite beating Q4 earnings estimates, the company remains unprofitable with negative margins. The consensus among analysts is a "Moderate Buy" with an average target price of $24.67.
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
OrthoPediatrics Corp. announced strong financial results for Q4 and full year 2025, with record annual revenue of $236.3 million, up 15%. The company achieved its first quarter of positive free cash flow, generating $10 million in Q4 2025, and provided a positive 2026 revenue guidance of $262.0 million to $266.0 million. These results highlight the company's operational execution, strategic advancements, and its continued leadership in pediatric orthopedics.
OrthoPediatrics Corp. (NASDAQ:KIDS) Q4 2025 Earnings Call Transcript
OrthoPediatrics Corp. reported strong financial results for Q4 2025, with a 17% revenue increase and their first quarter of positive free cash flow, exceeding earnings expectations with an EPS of $-0.26 against an expected $-0.37. The company highlighted significant product innovations, including new systems for trauma, deformity, and scoliosis, and reiterated its 2026 revenue guidance of $262 million to $266 million and an adjusted EBITDA of approximately $25 million with free cash flow breakeven. They also discussed plans to expand into other pediatric subspecialties and leverage new technologies to further drive growth and profitability.
OrthoPediatrics to Participate in Upcoming Conferences
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and The Citizens Life Sciences Conference on March 10, 2026. Both events will feature a fireside chat format, with audio webcasts available on the company's investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 85 products across trauma, deformity, scoliosis, and sports medicine.
OrthoPediatrics to Participate in Upcoming Conferences
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in two investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and The Citizens Life Sciences Conference on March 10, 2026. The company specializes in pediatric orthopedics, offering over 85 products across various categories, and will make audio webcasts of the discussions available online.
OrthoPediatrics (NASDAQ:KIDS) Given New $24.00 Price Target at BTIG Research
BTIG Research has raised its price target for OrthoPediatrics (NASDAQ:KIDS) from $23.00 to $24.00, maintaining a "buy" rating and suggesting a potential upside of 34.9% from its current price. The adjustment follows OrthoPediatrics' Q4 earnings beat, where the company exceeded EPS and revenue estimates and reiterated its FY2026 revenue guidance. Despite this positive outlook, the company remains unprofitable with negative margins, which analysts note will limit valuation growth until sustained profitability is achieved.
OrthoPediatrics (NASDAQ:KIDS) Given New $30.00 Price Target at Needham & Company LLC
Needham & Company LLC has increased its price target for OrthoPediatrics (NASDAQ:KIDS) to $30.00 from $26.00, maintaining a "buy" rating after the company beat Q4 earnings and revenue estimates. Despite the operational beats and reiterated FY2026 revenue guidance, OrthoPediatrics remains unprofitable, with analysts modeling a full-year EPS of -0.93, which could limit valuation expansion. The company specializes in orthopedic solutions for children and announced strong Q4 performance and an accelerating product innovation cycle.
OrthoPediatrics to Participate in Upcoming Conferences
OrthoPediatrics Corp. (Nasdaq: KIDS) announced its participation in two upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference on March 3, 2026, and The Citizens Life Sciences Conference on March 10, 2026. Both events will feature a fireside chat format, with audio webcasts and replays available on the company's investor relations website. The company specializes in pediatric orthopedics, offering over 85 products for various conditions.
OrthoPediatrics (NASDAQ: KIDS) details 2025 growth and 2026 outlook
OrthoPediatrics Corp. (NASDAQ: KIDS) provided an investor presentation reviewing its 2025 financial performance and outlining its 2026 outlook. In 2025, the company achieved $236.3 million in revenue, a 15% increase, with a gross margin of 73%. Looking ahead to 2026, OrthoPediatrics targets revenue between $262.0 million and $266.0 million, approximately $25 million in Adjusted EBITDA, and breakeven free cash flow, while continuing to invest in new technologies and clinic expansion.
OrthoPediatrics: Fourth Quarter Financial Overview
OrthoPediatrics Corp. reported a fourth-quarter net loss of $10.1 million, or 43 cents per share, with an adjusted loss of 26 cents per share. Despite the loss, the company exceeded analyst revenue expectations, generating $61.6 million for the quarter and $236.3 million for the full year. OrthoPediatrics projects future annual revenue to be between $262 million and $266 million.
OrthoPediatrics (KIDS) grows 2025 revenue 15% and targets 2026 cash breakeven
OrthoPediatrics Corp. reported robust financial results for 2025, with revenue climbing 15% to $236.3 million and a significant improvement in adjusted EBITDA to $14.8 million. Despite this growth, the company recorded a net loss of $39.6 million, though it achieved its first quarter of positive free cash flow in Q4 2025. Looking ahead to 2026, OrthoPediatrics projects continued revenue growth of 11-13% to reach $262.0-$266.0 million and aims for breakeven free cash flow.
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
OrthoPediatrics Corp. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported record full-year 2025 revenue of $236.3 million, a 15% increase year-over-year, and generated $7.8 million in free cash flow in Q4 2025, contributing to a 60% reduction in full year 2025 free cash flow usage compared to 2024. For full year 2026, the company expects revenue guidance between $273.0 million and $277.0 million, representing 11%-13% growth over 2025.
OrthoPediatrics (KIDS) Expected to Announce Earnings on Thursday
OrthoPediatrics (NASDAQ:KIDS) is expected to announce its Q4 2025 earnings after the market closes on Thursday, February 26th, 2026. Analysts project a loss of ($0.29) per share on revenue of $61.27 million. The stock currently holds a "Moderate Buy" consensus rating with an average target price of $23.89, and institutional investors own approximately 69% of the shares.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results, with a live and archived webcast available on its investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering over 85 products across trauma, deformity, scoliosis, and sports medicine.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after market close. The company will host a conference call on the same day at 4:30 p.m. ET to discuss these results, with a live and archived webcast available on their investor relations website. OrthoPediatrics specializes in pediatric orthopedics, offering over 85 products across various categories and distributing them globally.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss the results, with a live and archived webcast available on its investor relations website. OrthoPediatrics focuses exclusively on pediatric orthopedics, offering over 85 products globally.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on February 26, 2026, after the market closes. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results. A webcast of the event will be available on their investor relations website.
OrthoPediatrics Corp: Niche Pediatric Ortho Specialist Tests Investor Patience As Growth Story Repri
OrthoPediatrics Corp (KIDS), a specialized pediatric orthopedics company, is testing investor patience as its growth story reprices, with the stock trading in the lower half of its 52-week range despite solid revenue growth. Investors are grappling with the company's struggle to translate its clinical niche into sustained profitability and shareholder returns amid a cautious market for small-cap growth names. The future performance hinges on the company's ability to maintain revenue growth, convert innovations into market share gains, and navigate the broader economic landscape to achieve stronger profitability.
OrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. (Nasdaq: KIDS) announced it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, after the market closes. The company will also host a conference call at 4:30 p.m. ET on the same day to discuss these results. A live and archived webcast of the event will be available on the Investors page of their website.
